Paper Details

  1. Home
  2. Paper Details

Frequency of pre-treatment may not increase the immune-related adverse events of RCC patients treated with nivolumab.

Author: AndoRyosuke, IshiharaTakuma, ItoToshiki, KoieTakuya, MiyakeHideaki, MizutaniKosuke, ShirokiRyoichi, TakaharaKiyoshi, YasuiTakahiro

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.

Overview

This study investigates the association between immune-related adverse events (irAEs) due to nivolumab treatment and the number of prior targeted therapies in patients with renal cell carcinoma (RCC). The results suggest that the number of prior therapies is associated with higher grades of irAEs, but not the incidence of irAEs.
Paper Details　
Original Abstract of the Article :
Nivolumab has shown good prognosis in renal cell carcinoma (RCC) patients previously treated with targeted therapy. We aimed to study irAE (immune-related adverse event) due to nivolumab and numbers of previous treatment lines in RCC patients. Between October 2016 and November 2019, 114 patients wer...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021322/

データ提供：米国国立医学図書館（NLM）

Nivolumab: A Powerful Oasis in the Desert of Renal Cell Carcinoma

Renal cell carcinoma (RCC), a type of kidney cancer, is a formidable adversary, often resistant to conventional therapies. This research investigates the effectiveness of nivolumab, an immune checkpoint inhibitor, in treating RCC patients previously treated with targeted therapy. The authors delve into the incidence of immune-related adverse events (irAEs) associated with nivolumab, exploring whether the number of previous treatment lines influences the likelihood of these side effects. Their research is a beacon of hope in the desert of RCC treatment, offering a new perspective on managing this complex disease.

Navigating the Desert of Immune-Related Adverse Events

The study, analyzing data from 114 RCC patients treated with nivolumab, found no statistically significant relationship between the number of previous therapies and the incidence or severity of irAEs. This suggests that the risk of irAEs with nivolumab is not significantly influenced by prior treatment history. This finding is a significant step forward in understanding the safety profile of nivolumab, offering reassurance to patients and healthcare providers.

A Strategic Approach in the Desert of RCC

The research highlights the importance of careful monitoring for irAEs in patients treated with nivolumab, regardless of the number of previous therapies. This underscores the need for vigilant observation and prompt management of any potential side effects.

Dr.Camel's Conclusion

This research offers a valuable insight into the effectiveness and safety of nivolumab in treating RCC. The findings provide a glimmer of hope in the desert of RCC treatment, suggesting that nivolumab can be a powerful tool, even for patients who have undergone multiple lines of therapy. However, navigating this treatment landscape requires a strategic approach, with careful monitoring for irAEs and a collaborative partnership between patients and their healthcare providers.

Date :
  1. Date Completed 2021-04-14
  2. Date Revised 2023-01-03
Further Info :

Pubmed ID

33787647

DOI: Digital Object Identifier

PMC8021322

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.